Published in Cold Spring Harb Perspect Med on July 01, 2012
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature (2013) 3.55
Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med (2012) 2.56
Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science (2016) 2.35
Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med (2012) 2.02
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Neuroscience. Garbage truck of the brain. Science (2013) 1.97
The key role of transient receptor potential melastatin-2 channels in amyloid-β-induced neurovascular dysfunction. Nat Commun (2014) 1.66
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron (2015) 1.49
Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid. Brain (2014) 1.43
Relationship of regional brain β-amyloid to gait speed. Neurology (2015) 1.43
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. Brain (2016) 1.41
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron (2014) 1.33
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J (2013) 1.31
The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci (2013) 1.30
Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron (2014) 1.19
Deciphering Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J Clin Invest (2014) 1.15
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2014) 1.07
Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease. J Neurosci (2015) 1.03
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol (2014) 1.01
Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease. J Neurosci (2015) 1.01
The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease. Front Aging Neurosci (2014) 1.01
Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener (2014) 0.99
DISC1 regulates trafficking and processing of APP and Aβ generation. Mol Psychiatry (2014) 0.98
GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease. Front Cell Neurosci (2014) 0.98
Protein amyloids develop an intrinsic fluorescence signature during aggregation. Analyst (2013) 0.98
Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. Epilepsy Behav (2013) 0.98
Early etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol (2015) 0.97
Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition. Front Aging Neurosci (2014) 0.96
Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat Nanotechnol (2014) 0.94
Heat shock proteins in neurodegenerative disorders and aging. J Cell Commun Signal (2014) 0.93
Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging (2014) 0.93
Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease. J Alzheimers Dis (2015) 0.93
Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. Neurobiol Dis (2014) 0.92
Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease. Mol Ther (2013) 0.92
Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med (2015) 0.92
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A (2016) 0.92
Brain and circulating levels of Aβ1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke (2012) 0.91
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One (2014) 0.91
Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. J Neural Transm (Vienna) (2012) 0.91
HSV-1 and Alzheimer's disease: more than a hypothesis. Front Pharmacol (2014) 0.91
Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background. Neural Plast (2015) 0.91
Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Curr Alzheimer Res (2015) 0.90
Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem Pharmacol (2014) 0.90
Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine (2012) 0.89
Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol (2014) 0.89
SUMO and Alzheimer's disease. Neuromolecular Med (2013) 0.89
Structural biology of presenilin 1 complexes. Mol Neurodegener (2014) 0.88
Opposite Neural Trajectories of Apolipoprotein E ϵ4 and ϵ2 Alleles with Aging Associated with Different Risks of Alzheimer's Disease. Cereb Cortex (2014) 0.88
Aggregate-depleted brain fails to induce Aβ deposition in a mouse model of Alzheimer's disease. PLoS One (2014) 0.88
Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicity. Sci Rep (2013) 0.87
Brains from non-Alzheimer's individuals containing amyloid deposits accelerate Aβ deposition in vivo. Acta Neuropathol Commun (2013) 0.87
Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs. Front Aging Neurosci (2014) 0.86
Integrity of mGluR-LTD in the associative/commissural inputs to CA3 correlates with successful aging in rats. J Neurosci (2013) 0.86
APP Receptor? To Be or Not To Be. Trends Pharmacol Sci (2016) 0.85
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Amyloid-β and proinflammatory cytokines utilize a prion protein-dependent pathway to activate NADPH oxidase and induce cofilin-actin rods in hippocampal neurons. PLoS One (2014) 0.85
The Sorting Receptor SorCS1 Regulates Trafficking of Neurexin and AMPA Receptors. Neuron (2015) 0.85
Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells. J Mol Cell Cardiol (2014) 0.85
Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease. Mol Neurodegener (2014) 0.85
Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. J Biol Chem (2015) 0.84
Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist. J Alzheimers Dis (2014) 0.84
Intraneuronal Aβ accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3. Neurobiol Aging (2014) 0.84
Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A (2015) 0.83
Brain amyloid-β burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci (2015) 0.83
Novel lipid signaling pathways in Alzheimer's disease pathogenesis. Biochem Pharmacol (2013) 0.83
Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Front Behav Neurosci (2014) 0.83
The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. Neurobiol Aging (2015) 0.83
CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases. Mol Psychiatry (2015) 0.83
Role of endosomes and lysosomes in human disease. Cold Spring Harb Perspect Biol (2014) 0.83
The adipocyte differentiation protein APMAP is an endogenous suppressor of Aβ production in the brain. Hum Mol Genet (2014) 0.82
Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease. Front Aging Neurosci (2015) 0.82
STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity. Mol Neurodegener (2015) 0.82
Amyloid-β and Alzheimer's disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions. Cell Death Dis (2013) 0.82
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. Mol Neurodegener (2014) 0.82
Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents. ACS Chem Neurosci (2013) 0.82
d-serine levels in Alzheimer's disease: implications for novel biomarker development. Transl Psychiatry (2015) 0.82
Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. BMC Biol (2016) 0.82
Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease. Sci Transl Med (2016) 0.81
Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease. Sci Signal (2016) 0.81
Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of Alzheimer's Disease. PLoS One (2015) 0.81
Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener (2016) 0.80
Fragile X mental retardation protein: from autism to neurodegenerative disease. Front Cell Neurosci (2015) 0.80
β-Amyloid peptides and amyloid plaques in Alzheimer's disease. Neurotherapeutics (2015) 0.80
APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. Elife (2015) 0.80
Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats. ACS Chem Neurosci (2015) 0.80
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast (2016) 0.80
Dissecting Alzheimer disease in Down syndrome using mouse models. Front Behav Neurosci (2015) 0.79
Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics. Int J Alzheimers Dis (2015) 0.79
Is L-methionine a trigger factor for Alzheimer's-like neurodegeneration?: Changes in Aβ oligomers, tau phosphorylation, synaptic proteins, Wnt signaling and behavioral impairment in wild-type mice. Mol Neurodegener (2015) 0.79
Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. Biochim Biophys Acta (2016) 0.79
Titration of biologically active amyloid-β seeds in a transgenic mouse model of Alzheimer's disease. Sci Rep (2015) 0.78
Lessons from two prevalent amyloidoses-what amylin and Aβ have in common. Front Aging Neurosci (2013) 0.78
Andrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1 mice. Mol Neurodegener (2014) 0.78
Impairments in neurogenesis are not tightly linked to depressive behavior in a transgenic mouse model of Alzheimer's disease. PLoS One (2013) 0.78
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
APP processing and synaptic function. Neuron (2003) 8.37
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
The molecular pathology of Alzheimer's disease. Neuron (1991) 8.21
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol (1990) 6.79
AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron (2006) 6.76
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron (2007) 6.60
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science (2004) 5.76
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Synaptic AMPA receptor plasticity and behavior. Neuron (2009) 5.58
Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem (1997) 5.07
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci (2010) 5.03
Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 5.00
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron (2004) 4.21
Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol (1997) 4.16
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94
Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci (1999) 3.92
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science (2008) 3.59
Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci (2010) 3.36
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
A network dysfunction perspective on neurodegenerative diseases. Nature (2006) 3.33
The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry (2000) 3.31
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci (2005) 3.23
Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci (2008) 3.21
Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol (2009) 3.12
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J (2001) 3.08
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
The many faces of tau. Neuron (2011) 2.89
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem (2001) 2.77
Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem (1995) 2.68
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci (2004) 2.64
Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med (2012) 2.56
Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J (2007) 2.39
Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem (1996) 2.34
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci (2009) 2.33
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci (2009) 2.31
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med (2010) 2.25
Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci (2009) 2.18
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging (2005) 2.06
Long-term synaptic plasticity in hippocampal interneurons. Nat Rev Neurosci (2007) 1.96
Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res (1998) 1.88
Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A (1995) 1.87
Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci (2011) 1.79
Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J Neurosci (2005) 1.79
Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci (2006) 1.75
Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet (1999) 1.74
Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol (2007) 1.69
Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. Cell Stem Cell (2009) 1.68
Apolipoprotein E and cognitive performance. Nature (2000) 1.64
Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology (1999) 1.60
Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci (2002) 1.56
Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci (2004) 1.55
Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci (2001) 1.50
Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci (2011) 1.43
The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium (2010) 1.40
Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci (2009) 1.40
Is your brain really necessary? Science (1980) 1.39
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27
Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron (2004) 4.88
Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci (2006) 4.14
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A (2003) 3.36
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci (2005) 2.57
A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci (2007) 2.48
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron (2003) 2.43
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry (2009) 2.38
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem (2003) 2.22
Purification and characterization of the human gamma-secretase complex. Biochemistry (2004) 2.18
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A (2002) 2.16
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem (2008) 2.00
Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem (2007) 1.95
The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J Neurochem (2011) 1.93
Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem (2003) 1.83
Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry (2007) 1.81
Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev (2008) 1.79
Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A (2006) 1.77
Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet (2007) 1.76
Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers. Neuron (2013) 1.76
Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol (2008) 1.75
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry (2004) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 1.58
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53
Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One (2009) 1.52
Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid (2002) 1.52
Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem (2004) 1.49
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol (2006) 1.48
Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol (2008) 1.45
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem (2005) 1.45
A seed for Alzheimer amyloid in the brain. J Neurosci (2004) 1.45
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem (2005) 1.44
Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J (2004) 1.43
Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). Biochemistry (2003) 1.42
Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol (2011) 1.42
Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem (2003) 1.42
Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol (2012) 1.37
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci (2005) 1.34
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis (2003) 1.32
Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic (2008) 1.30
Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. J Neurosci (2010) 1.29
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry (2005) 1.26
Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis (2008) 1.23
gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry (2003) 1.22
Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem (2003) 1.22
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem (2007) 1.22
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22
Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci (2004) 1.19
Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol (2011) 1.17
LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis (2008) 1.15
Alzheimer disease in 2020. Cold Spring Harb Perspect Med (2012) 1.15
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging (2010) 1.14
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis (2007) 1.13
Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis (2003) 1.11
Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol Dis (2005) 1.10
Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. Traffic (2003) 1.08
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol (2007) 1.08
Toward structural elucidation of the gamma-secretase complex. Structure (2009) 1.07
Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem (2003) 1.06
Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. J Biol Chem (2002) 1.06
Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc Natl Acad Sci U S A (2008) 1.06
Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem (2007) 1.05
The ups and downs of Abeta. Nat Med (2006) 1.04
Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry (2012) 1.03
Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One (2009) 1.03
Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol (2011) 1.03
Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. Mol Neurodegener (2011) 1.02
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord (2011) 1.01